{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:16:50Z","timestamp":1788898610952,"version":"build-2803163510"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Moyira Elizabeth Vine Fund, Australia Deputy Vice Chancellor-Start Up Funds, University of Sydney"},{"name":"Australian Government Research Training Program (RTP) Scholarship"},{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["Programme to increase the Mobility of Students from Germany (PROMOS)"],"award-info":[{"award-number":["Programme to increase the Mobility of Students from Germany (PROMOS)"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["Germany Scholarship"],"award-info":[{"award-number":["Germany Scholarship"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Endocannabinoids (eCBs) are lipid-derived neuromodulators that regulate numerous neurophysiological processes by modulating synaptic transmission. Synthesised on demand in response to increased postsynaptic intracellular calcium or activation of postsynaptic G-protein coupled receptors, eCBs are rapidly degraded, resulting in transient, tightly regulated signalling. Dysregulation in the endocannabinoid system (ECS), including altered peripheral and central eCB concentrations and\/or cannabinoid-1 receptor (CB\n                    <jats:sub>1<\/jats:sub>\n                    R) expression, has been observed across psychiatric syndromes, including major depressive disorder, psychotic disorders, and post-traumatic stress disorder (PTSD). These associations have prompted growing interest in pharmacological strategies targeting the ECS. Though medical cannabis is increasingly prescribed for psychiatric symptoms, its clinical use remains controversial due to limited high-quality evidence, psychotropic side effects, and regulatory constraints. An alternative is to enhance the signalling of a principal eCB, anandamide (AEA), potentially offering more physiologically constrained CB\n                    <jats:sub>1<\/jats:sub>\n                    R engagement, by inhibiting fatty acid amide hydrolase (FAAH), the main enzyme degrading AEA and its congener, N-acylethanolamines (NAE), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). This review consolidates recent clinical evidence for FAAH inhibitors, examining their influence on AEA, safety and efficacy in ameliorating symptoms across a range of psychiatric conditions, including depression, anxiety, PTSD, and cannabis use disorder (CUD). Presently, only two compounds, PF-04457845 (JZP150) and JNJ-42165279, have progressed to Phase II trials, demonstrating modest clinical benefit in CUD, with no efficacy in PTSD or osteoarthritis pain. Herein, we discuss emerging insights, safety considerations, broader mechanistic implications, and future directions for FAAH-targeted therapeutics, advocating for a precision medicine approach to realise their potential in the treatment of psychiatric disorders.\n                  <\/jats:p>","DOI":"10.1038\/s41398-026-04120-4","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:05:12Z","timestamp":1779980712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhancing anandamide signalling through fatty acid amide hydrolase inhibition: An update on the pharmacological strategy for treating psychiatric disorders"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-2638","authenticated-orcid":false,"given":"Timothy A.","family":"Couttas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Jieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix R.","family":"Golla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Markus","family":"Leweke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3559-1846","authenticated-orcid":false,"given":"Cathrin","family":"Rohleder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"4120_CR1","first-page":"607","volume":"6","author":"HC Lu","year":"2021","unstructured":"Lu HC, Mackie K. Review of the Endocannabinoid System. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6:607\u201315.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"4120_CR2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00213-009-1591-7","volume":"206","author":"D Koethe","year":"2009","unstructured":"Koethe D, Hoyer C, Leweke FM. The endocannabinoid system as a target for modelling psychosis. Psychopharmacology (Berl). 2009;206:551\u201361.","journal-title":"Psychopharmacology (Berl)"},{"key":"4120_CR3","doi-asserted-by":"publisher","first-page":"110096","DOI":"10.1016\/j.pnpbp.2020.110096","volume":"106","author":"R Garani","year":"2021","unstructured":"Garani R, Watts JJ, Mizrahi R. Endocannabinoid system in psychotic and mood disorders, a review of human studies. Prog Neuropsychopharmacol Biol Psychiatry. 2021;106:110096.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4120_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/brainsci13020325","volume":"13","author":"A Hasbi","year":"2023","unstructured":"Hasbi A, Madras BK, George SR. Endocannabinoid system and exogenous cannabinoids in depression and anxiety: a review. Brain Sci. 2023;13:325.","journal-title":"Brain Sci"},{"key":"4120_CR5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd1495","volume":"3","author":"V Di Marzo","year":"2004","unstructured":"Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3:771\u201384.","journal-title":"Nat Rev Drug Discov"},{"key":"4120_CR6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrn1247","volume":"4","author":"D Piomelli","year":"2003","unstructured":"Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873\u201384.","journal-title":"Nat Rev Neurosci"},{"key":"4120_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1054\/plef.2001.0341","volume":"66","author":"RG Pertwee","year":"2002","unstructured":"Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids. 2002;66:101\u201321.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"4120_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/3-540-26573-2_10","volume":"168","author":"K Mackie","year":"2005","unstructured":"Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. 2005;168:299\u2013325.","journal-title":"Handb Exp Pharmacol"},{"key":"4120_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/bs.apha.2017.03.009","volume":"80","author":"DT Kho","year":"2017","unstructured":"Kho DT, Glass M, Graham ES. Is the Cannabinoid CB(2) Receptor a Major Regulator of the Neuroinflammatory Axis of the Neurovascular Unit in Humans?. Adv Pharmacol. 2017;80:367\u201396.","journal-title":"Adv Pharmacol"},{"key":"4120_CR10","doi-asserted-by":"publisher","first-page":"S319","DOI":"10.1007\/BF02562332","volume":"34","author":"V Di Marzo","year":"1999","unstructured":"Di Marzo V, De Petrocellis L, Bisogno T, Melck D. Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments. Lipids. 1999;34:S319\u201325.","journal-title":"Lipids"},{"key":"4120_CR11","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.1470919","volume":"258","author":"WA Devane","year":"1992","unstructured":"Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946\u20139.","journal-title":"Science"},{"key":"4120_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","volume":"50","author":"R Mechoulam","year":"1995","unstructured":"Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83\u201390.","journal-title":"Biochem Pharmacol"},{"key":"4120_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","volume":"79","author":"HC Lu","year":"2016","unstructured":"Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry. 2016;79:516\u201325.","journal-title":"Biol Psychiatry"},{"key":"4120_CR14","doi-asserted-by":"publisher","first-page":"885904","DOI":"10.3389\/fpsyt.2022.885904","volume":"13","author":"TA Couttas","year":"2022","unstructured":"Couttas TA, Jieu B, Rohleder C, Leweke FM. Current state of fluid lipid biomarkers for personalized diagnostics and therapeutics in schizophrenia spectrum disorders and related psychoses: a narrative review. Front Psychiatry. 2022;13:885904.","journal-title":"Front Psychiatry"},{"key":"4120_CR15","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.bbalip.2014.12.014","volume":"1851","author":"CP Muller","year":"2015","unstructured":"Muller CP, Reichel M, Muhle C, Rhein C, Gulbins E, Kornhuber J. Brain membrane lipids in major depression and anxiety disorders. Biochim Biophys Acta. 2015;1851:1052\u201365.","journal-title":"Biochim Biophys Acta"},{"key":"4120_CR16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/j.1476-5381.2011.01364.x","volume":"163","author":"AC Howlett","year":"2011","unstructured":"Howlett AC, Reggio PH, Childers SR, Hampson RE, Ulloa NM, Deutsch DG. Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol. 2011;163:1329\u201343.","journal-title":"Br J Pharmacol"},{"key":"4120_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.conb.2014.03.017","volume":"29","author":"T Ohno-Shosaku","year":"2014","unstructured":"Ohno-Shosaku T, Kano M. Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol. 2014;29:1\u20138.","journal-title":"Curr Opin Neurobiol"},{"key":"4120_CR18","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"RG Pertwee","year":"2010","unstructured":"Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev. 2010;62:588\u2013631.","journal-title":"Pharmacol Rev"},{"key":"4120_CR19","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1098\/rstb.2011.0382","volume":"367","author":"V Di Marzo","year":"2012","unstructured":"Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand?. Philos Trans R Soc Lond B Biol Sci. 2012;367:3216\u201328.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"4120_CR20","first-page":"294","volume":"10","author":"DA Kendall","year":"2016","unstructured":"Kendall DA, Yudowski GA. Cannabinoid receptors in the central nervous system: their signaling and roles in disease. Front Cell Neurosci. 2016;10:294.","journal-title":"Front Cell Neurosci"},{"key":"4120_CR21","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.2174\/138161212802884843","volume":"18","author":"FM Leweke","year":"2012","unstructured":"Leweke FM. Anandamide dysfunction in prodromal and established psychosis. Curr Pharm Des. 2012;18:5188\u201393.","journal-title":"Curr Pharm Des"},{"key":"4120_CR22","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/00001756-199906030-00008","volume":"10","author":"FM Leweke","year":"1999","unstructured":"Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10:1665\u20139.","journal-title":"Neuroreport"},{"key":"4120_CR23","doi-asserted-by":"crossref","unstructured":"Leweke, FM, Rohleder C Chapter 4 - Putative Role of Endocannabinoids in Schizophrenia, in The Endocannabinoid System, E Murillo-Rodr\u00edguez, Editor. 2017, Academic Press. p.83-113.","DOI":"10.1016\/B978-0-12-809666-6.00004-6"},{"key":"4120_CR24","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","volume":"29","author":"A Giuffrida","year":"2004","unstructured":"Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29:2108\u201314.","journal-title":"Neuropsychopharmacology"},{"key":"4120_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","volume":"194","author":"D Koethe","year":"2009","unstructured":"Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry. 2009;194:371\u20132.","journal-title":"Br J Psychiatry"},{"key":"4120_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/bmj.38267.664086.63","volume":"330","author":"C Henquet","year":"2005","unstructured":"Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005;330:11.","journal-title":"BMJ"},{"key":"4120_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/aje\/kwf043","volume":"156","author":"J van Os","year":"2002","unstructured":"van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156:319\u201327.","journal-title":"Am J Epidemiol"},{"key":"4120_CR28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/bmj.325.7374.1199","volume":"325","author":"S Zammit","year":"2002","unstructured":"Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325:1199.","journal-title":"BMJ"},{"key":"4120_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","volume":"94","author":"FM Leweke","year":"2007","unstructured":"Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res. 2007;94:29\u201336.","journal-title":"Schizophr Res"},{"key":"4120_CR30","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1177\/02698811221148604","volume":"37","author":"A Bassir Nia","year":"2023","unstructured":"Bassir Nia A, Gibson CL, Spriggs SA, Jankowski SE, DeFrancisco D, Swift A, et al. Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis. J Psychopharmacol. 2023;37:484\u20139.","journal-title":"J Psychopharmacol"},{"key":"4120_CR31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1192\/bjp.bp.112.121178","volume":"202","author":"CJ Morgan","year":"2013","unstructured":"Morgan CJ, Page E, Schaefer C, Chatten K, Manocha A, Gulati S, et al. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br J Psychiatry. 2013;202:381\u20132.","journal-title":"Br J Psychiatry"},{"key":"4120_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02410-9","volume":"13","author":"DY Hua","year":"2023","unstructured":"Hua DY, Hindocha C, Baio G, Lees R, Shaban N, Morgan CJ, et al. Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder. Transl Psychiatry. 2023;13:131.","journal-title":"Transl Psychiatry"},{"key":"4120_CR33","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.psyneuen.2009.03.013","volume":"34","author":"MN Hill","year":"2009","unstructured":"Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology. 2009;34:1257\u201362.","journal-title":"Psychoneuroendocrinology"},{"key":"4120_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1055\/s-2007-993211","volume":"41","author":"MN Hill","year":"2008","unstructured":"Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry. 2008;41:48\u201353.","journal-title":"Pharmacopsychiatry"},{"key":"4120_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep07796","volume":"5","author":"S Ogawa","year":"2015","unstructured":"Ogawa S, Hattori K, Sasayama D, Yokota Y, Matsumura R, Matsuo J, et al. Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder. Sci Rep. 2015;5:7796.","journal-title":"Sci Rep"},{"key":"4120_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.neuropharm.2019.02.026","volume":"149","author":"P Romero-Sanchiz","year":"2019","unstructured":"Romero-Sanchiz P, Nogueira-Arjona R, Pastor A, Araos P, Serrano A, Boronat A, et al. Plasma concentrations of oleoylethanolamide in a primary care sample of depressed patients are increased in those treated with selective serotonin reuptake inhibitor-type antidepressants. Neuropharmacology. 2019;149:212\u201320.","journal-title":"Neuropharmacology"},{"key":"4120_CR37","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/npp.2012.100","volume":"37","author":"A Dlugos","year":"2012","unstructured":"Dlugos A, Childs E, Stuhr KL, Hillard CJ, de Wit H. Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology. 2012;37:2416\u201327.","journal-title":"Neuropsychopharmacology"},{"key":"4120_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7395","volume":"6","author":"I Dincheva","year":"2015","unstructured":"Dincheva I, Drysdale AT, Hartley CA, Johnson DC, Jing D, King EC, et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun. 2015;6:6395.","journal-title":"Nat Commun"},{"key":"4120_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.neuroscience.2011.12.030","volume":"204","author":"MN Hill","year":"2012","unstructured":"Hill MN, Tasker JG. Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience. 2012;204:5\u201316.","journal-title":"Neuroscience"},{"key":"4120_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/npp.2015.166","volume":"41","author":"M Morena","year":"2016","unstructured":"Morena M, Patel S, Bains JS, Hill MN. Neurobiological Interactions Between Stress and the Endocannabinoid System. Neuropsychopharmacology. 2016;41:80\u2013102.","journal-title":"Neuropsychopharmacology"},{"key":"4120_CR41","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0006-3223(96)00489-1","volume":"42","author":"MB Stein","year":"1997","unstructured":"Stein MB, Yehuda R, Koverola C, Hanna C. Enhanced dexamethasone suppression of plasma cortisol in adult women traumatized by childhood sexual abuse. Biol Psychiatry. 1997;42:680\u20136.","journal-title":"Biol Psychiatry"},{"key":"4120_CR42","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1111\/acer.13210","volume":"40","author":"PA Spagnolo","year":"2016","unstructured":"Spagnolo PA, Ramchandani VA, Schwandt ML, Kwako LE, George DT, Mayo LM, et al. FAAH gene variation moderates stress response and symptom severity in patients with posttraumatic stress disorder and comorbid alcohol dependence. Alcohol Clin Exp Res. 2016;40:2426\u201334.","journal-title":"Alcohol Clin Exp Res"},{"key":"4120_CR43","doi-asserted-by":"publisher","first-page":"247054702211072","DOI":"10.1177\/24705470221107290","volume":"6","author":"NA Leen","year":"2022","unstructured":"Leen NA, de Weijer AD, van Rooij SJH, Kennis M, Baas JMP, Geuze E. The role of the endocannabinoids 2-AG and anandamide in clinical symptoms and treatment outcome in veterans with PTSD. Chronic Stress (Thousand Oaks). 2022;6:24705470221107290.","journal-title":"Chronic Stress (Thousand Oaks)"},{"key":"4120_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopsycho.2019.04.002","volume":"145","author":"KM Crombie","year":"2019","unstructured":"Crombie KM, Leitzelar BN, Brellenthin AG, Hillard CJ, Koltyn KF. Loss of exercise- and stress-induced increases in circulating 2-arachidonoylglycerol concentrations in adults with chronic PTSD. Biol Psychol. 2019;145:1\u20137.","journal-title":"Biol Psychol"},{"key":"4120_CR45","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00406-013-0470-8","volume":"264","author":"C Schaefer","year":"2014","unstructured":"Schaefer C, Enning F, Mueller JK, Bumb JM, Rohleder C, Odorfer TM, et al. Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. Eur Arch Psychiatry Clin Neurosci. 2014;264:459\u201363.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"4120_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01808-1","volume":"12","author":"TA deRoon-Cassini","year":"2022","unstructured":"deRoon-Cassini TA, Bergner CL, Chesney SA, Schumann NR, Lee TS, Brasel KJ, et al. Circulating endocannabinoids and genetic polymorphisms as predictors of posttraumatic stress disorder symptom severity: heterogeneity in a community-based cohort. Transl Psychiatry. 2022;12:48.","journal-title":"Transl Psychiatry"},{"key":"4120_CR47","doi-asserted-by":"publisher","first-page":"e62741","DOI":"10.1371\/journal.pone.0062741","volume":"8","author":"D Hauer","year":"2013","unstructured":"Hauer D, Schelling G, Gola H, Campolongo P, Morath J, Roozendaal B, et al. Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS One. 2013;8:e62741.","journal-title":"PLoS One"},{"key":"4120_CR48","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/mp.2013.61","volume":"18","author":"A Neumeister","year":"2013","unstructured":"Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18:1034\u201340.","journal-title":"Mol Psychiatry"},{"key":"4120_CR49","doi-asserted-by":"publisher","first-page":"102656","DOI":"10.1016\/j.janxdis.2022.102656","volume":"93","author":"C Botsford","year":"2023","unstructured":"Botsford C, Brellenthin AG, Cisler JM, Hillard CJ, Koltyn KF, Crombie KM. Circulating endocannabinoids and psychological outcomes in women with PTSD. J Anxiety Disord. 2023;93:102656.","journal-title":"J Anxiety Disord"},{"key":"4120_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.31887\/DCNS.2020.22.3\/pfadda","volume":"22","author":"M Scherma","year":"2020","unstructured":"Scherma M, Muntoni AL, Riedel G, Fratta W, Fadda P. Cannabinoids and their therapeutic applications in mental disorders. Dialogues Clin Neurosci. 2020;22:271\u20139.","journal-title":"Dialogues Clin Neurosci"},{"key":"4120_CR51","doi-asserted-by":"publisher","first-page":"586","DOI":"10.31128\/AJGP-04-21-5936","volume":"51","author":"M Berger","year":"2022","unstructured":"Berger M, Amminger GP, McGregor IS. Medicinal cannabis for the treatment of anxiety disorders. Aust J Gen Pract. 2022;51:586\u201392.","journal-title":"Aust J Gen Pract"},{"key":"4120_CR52","doi-asserted-by":"publisher","first-page":"729800","DOI":"10.3389\/fpsyt.2021.729800","volume":"12","author":"EL Martin","year":"2021","unstructured":"Martin EL, Strickland JC, Schlienz NJ, Munson J, Jackson H, Bonn-Miller MO, et al. Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial. Front Psychiatry. 2021;12:729800.","journal-title":"Front Psychiatry"},{"key":"4120_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/0706743719895195","volume":"65","author":"JV Pinto","year":"2020","unstructured":"Pinto JV, Saraf G, Frysch C, Vigo D, Keramatian K, Chakrabarty T, et al. Cannabidiol as a treatment for mood disorders: a systematic review. Can J Psychiatry. 2020;65:213\u201327.","journal-title":"Can J Psychiatry"},{"key":"4120_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ajad.12963","volume":"29","author":"SL Botsford","year":"2020","unstructured":"Botsford SL, Yang S, George TP. Cannabis and cannabinoids in mood and anxiety disorders: impact on illness onset and course, and assessment of therapeutic potential. Am J Addict. 2020;29:9\u201326.","journal-title":"Am J Addict"},{"key":"4120_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/YCO.0000000000000562","volume":"33","author":"VL Chadwick","year":"2020","unstructured":"Chadwick VL, Rohleder C, Koethe D, Leweke FM. Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. Curr Opin Psychiatry. 2020;33:20\u201342.","journal-title":"Curr Opin Psychiatry"},{"key":"4120_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00406-018-0970-7","volume":"269","author":"DJE Lowe","year":"2019","unstructured":"Lowe DJE, Sasiadek JD, Coles AS, George TP. Cannabis and mental illness: a review. Eur Arch Psychiatry Clin Neurosci. 2019;269:107\u201320.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"4120_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.","journal-title":"Transl Psychiatry"},{"key":"4120_CR58","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an Adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175:225\u201331.","journal-title":"Am J Psychiatry"},{"key":"4120_CR59","doi-asserted-by":"publisher","first-page":"e301027","DOI":"10.1136\/bmjment-2024-301027","volume":"27","author":"TA Couttas","year":"2024","unstructured":"Couttas TA, Boost C, Pahlisch F, Sykorova EB, Mueller JK, Jieu B, et al. Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers. BMJ Ment Health. 2024;27:e301027.","journal-title":"BMJ Ment Health"},{"key":"4120_CR60","doi-asserted-by":"publisher","first-page":"32332","DOI":"10.1074\/jbc.273.48.32332","volume":"273","author":"M Maccarrone","year":"1998","unstructured":"Maccarrone M, van der Stelt M, Rossi A, Veldink GA, Vliegenthart JF, Agro AF. Anandamide hydrolysis by human cells in culture and brain. J Biol Chem. 1998;273:32332\u20139.","journal-title":"J Biol Chem"},{"key":"4120_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/384083a0","volume":"384","author":"BF Cravatt","year":"1996","unstructured":"Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83\u20137.","journal-title":"Nature"},{"key":"4120_CR62","doi-asserted-by":"publisher","first-page":"36569","DOI":"10.1074\/jbc.M606646200","volume":"281","author":"BQ Wei","year":"2006","unstructured":"Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem. 2006;281:36569\u201378.","journal-title":"J Biol Chem"},{"key":"4120_CR63","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","volume":"163","author":"L De Petrocellis","year":"2011","unstructured":"De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163:1479\u201394.","journal-title":"Br J Pharmacol"},{"key":"4120_CR64","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1248\/bpb.19.1109","volume":"19","author":"K Watanabe","year":"1996","unstructured":"Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, Yoshimura H. Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull. 1996;19:1109\u201311.","journal-title":"Biol Pharm Bull"},{"key":"4120_CR65","doi-asserted-by":"publisher","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","volume":"290","author":"MW Elmes","year":"2015","unstructured":"Elmes MW, Kaczocha M, Berger WT, Leung K, Ralph BP, Wang L, et al. Fatty acid-binding proteins (FABPs) are intracellular carriers for Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem. 2015;290:8711\u201321.","journal-title":"J Biol Chem"},{"key":"4120_CR66","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1089\/can.2018.0031","volume":"3","author":"E Leishman","year":"2018","unstructured":"Leishman E, Manchanda M, Thelen R, Miller S, Mackie K, Bradshaw HB. Cannabidiol\u2019s upregulation of N-acyl ethanolamines in the central nervous system requires N-acyl phosphatidyl ethanolamine-specific Phospholipase D. Cannabis Cannabinoid Res. 2018;3:228\u201341.","journal-title":"Cannabis Cannabinoid Res"},{"key":"4120_CR67","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1074\/jbc.M109.058461","volume":"285","author":"M Kaczocha","year":"2010","unstructured":"Kaczocha M, Glaser ST, Chae J, Brown DA, Deutsch DG. Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2. J Biol Chem. 2010;285:2796\u2013806.","journal-title":"J Biol Chem"},{"key":"4120_CR68","doi-asserted-by":"publisher","first-page":"7327","DOI":"10.1021\/jm800311k","volume":"51","author":"M Seierstad","year":"2008","unstructured":"Seierstad M, Breitenbucher JG. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008;51:7327\u201343.","journal-title":"J Med Chem"},{"key":"4120_CR69","doi-asserted-by":"publisher","first-page":"8807","DOI":"10.1021\/jm3011146","volume":"55","author":"AD Favia","year":"2012","unstructured":"Favia AD, Habrant D, Scarpelli R, Migliore M, Albani C, Bertozzi SM, et al. Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase\/cyclooxygenase inhibitor. J Med Chem. 2012;55:8807\u201326.","journal-title":"J Med Chem"},{"key":"4120_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1527-3458.2006.00021.x","volume":"12","author":"D Piomelli","year":"2006","unstructured":"Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006;12:21\u201338.","journal-title":"CNS Drug Rev"},{"key":"4120_CR71","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nm803","volume":"9","author":"S Kathuria","year":"2003","unstructured":"Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003;9:76\u201381.","journal-title":"Nat Med"},{"key":"4120_CR72","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1021\/jm031140x","volume":"47","author":"M Mor","year":"2004","unstructured":"Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, et al. Cyclohexylcarbamic acid 3\u2019- or 4\u2019-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem. 2004;47:4998\u20135008.","journal-title":"J Med Chem"},{"key":"4120_CR73","doi-asserted-by":"publisher","first-page":"18620","DOI":"10.1073\/pnas.0509591102","volume":"102","author":"G Gobbi","year":"2005","unstructured":"Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA. 2005;102:18620\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4120_CR74","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.1007\/s12035-019-1596-0","volume":"56","author":"M Kruk-Slomka","year":"2019","unstructured":"Kruk-Slomka M, Banaszkiewicz I, Slomka T, Biala G. Effects of fatty acid amide hydrolase inhibitors acute administration on the positive and cognitive symptoms of schizophrenia in mice. Mol Neurobiol. 2019;56:7251\u201366.","journal-title":"Mol Neurobiol"},{"key":"4120_CR75","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1124\/jpet.104.069401","volume":"311","author":"AH Lichtman","year":"2004","unstructured":"Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther. 2004;311:441\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"4120_CR76","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1111\/j.1476-5381.2011.01445.x","volume":"165","author":"L Booker","year":"2012","unstructured":"Booker L, Kinsey SG, Abdullah RA, Blankman JL, Long JZ, Ezzili C, et al. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol. 2012;165:2485\u201396.","journal-title":"Br J Pharmacol"},{"key":"4120_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11606-1","volume":"7","author":"R Colangeli","year":"2017","unstructured":"Colangeli R, Pierucci M, Benigno A, Campiani G, Butini S, Di Giovanni G. The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity. Sci Rep. 2017;7:11152.","journal-title":"Sci Rep"},{"key":"4120_CR78","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bbr.2017.01.054","volume":"324","author":"Y Wang","year":"2017","unstructured":"Wang Y, Zhang X. FAAH inhibition produces antidepressant-like efforts of mice to acute stress via synaptic long-term depression. Behav Brain Res. 2017;324:138\u201345.","journal-title":"Behav Brain Res"},{"key":"4120_CR79","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-pharmtox-030220-112741","volume":"61","author":"N van Egmond","year":"2021","unstructured":"van Egmond N, Straub VM, van der Stelt M. Targeting endocannabinoid signaling: FAAH and MAG lipase inhibitors. Annu Rev Pharmacol Toxicol. 2021;61:441\u201363.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4120_CR80","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.biopsych.2021.07.019","volume":"91","author":"LM Mayo","year":"2022","unstructured":"Mayo LM, Rabinak CA, Hill MN, Heilig M. Targeting the endocannabinoid system in the treatment of posttraumatic stress disorder: a promising case of preclinical-clinical translation?. Biol Psychiatry. 2022;91:262\u201372.","journal-title":"Biol Psychiatry"},{"key":"4120_CR81","doi-asserted-by":"publisher","first-page":"111953","DOI":"10.1016\/j.ejmech.2019.111953","volume":"188","author":"RKP Tripathi","year":"2020","unstructured":"Tripathi RKP. A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents. Eur J Med Chem. 2020;188:111953.","journal-title":"Eur J Med Chem"},{"key":"4120_CR82","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/acs.jmedchem.6b00538","volume":"60","author":"W Tuo","year":"2017","unstructured":"Tuo W, Leleu-Chavain N, Spencer J, Sansook S, Millet R, Chavatte P. Therapeutic potential of fatty acid amide hydrolase, monoacylglycerol lipase, and N-acylethanolamine acid amidase inhibitors. J Med Chem. 2017;60:4\u201346.","journal-title":"J Med Chem"},{"key":"4120_CR83","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1124\/jpet.104.078980","volume":"313","author":"D Fegley","year":"2005","unstructured":"Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3\u2019-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther. 2005;313:352\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"4120_CR84","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.prostaglandins.2009.05.004","volume":"91","author":"A Giuffrida","year":"2010","unstructured":"Giuffrida A, McMahon LR. In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson\u2019s disease and abuse liability. Prostaglandins Other Lipid Mediat. 2010;91:90\u2013103.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"4120_CR85","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41401-018-0075-x","volume":"40","author":"M Scherma","year":"2019","unstructured":"Scherma M, Masia P, Satta V, Fratta W, Fadda P, Tanda G. Brain activity of anandamide: a rewarding bliss?. Acta Pharmacol Sin. 2019;40:309\u201323.","journal-title":"Acta Pharmacol Sin"},{"key":"4120_CR86","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.biopsych.2008.08.008","volume":"64","author":"Z Justinova","year":"2008","unstructured":"Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, et al. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry. 2008;64:930\u20137.","journal-title":"Biol Psychiatry"},{"key":"4120_CR87","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.1523\/JNEUROSCI.0951-05.2005","volume":"25","author":"Z Justinova","year":"2005","unstructured":"Justinova Z, Solinas M, Tanda G, Redhi GH, Goldberg SR. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci. 2005;25:5645\u201350.","journal-title":"J Neurosci"},{"key":"4120_CR88","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1016\/S0024-3205(98)00226-4","volume":"62","author":"PE Mallet","year":"1998","unstructured":"Mallet PE, Beninger RJ. Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance. Life Sci. 1998;62:2431\u20139.","journal-title":"Life Sci"},{"key":"4120_CR89","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.neuropharm.2007.08.011","volume":"54","author":"M Scherma","year":"2008","unstructured":"Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, et al. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology. 2008;54:129\u201340.","journal-title":"Neuropharmacology"},{"key":"4120_CR90","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1021\/ml100190t","volume":"2","author":"DS Johnson","year":"2011","unstructured":"Johnson DS, Stiff C, Lazerwith SE, Kesten SR, Fay LK, Morris M, et al. Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor. ACS Med Chem Lett. 2011;2:91\u201396.","journal-title":"ACS Med Chem Lett"},{"key":"4120_CR91","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1124\/jpet.111.180257","volume":"338","author":"K Ahn","year":"2011","unstructured":"Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, et al. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther. 2011;338:114\u201324.","journal-title":"J Pharmacol Exp Ther"},{"key":"4120_CR92","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/j.1365-2125.2011.04137.x","volume":"73","author":"GL Li","year":"2012","unstructured":"Li GL, Winter H, Arends R, Jay GW, Le V, Young T, et al. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharmacol. 2012;73:706\u201316.","journal-title":"Br J Clin Pharmacol"},{"key":"4120_CR93","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.pain.2012.04.020","volume":"153","author":"JP Huggins","year":"2012","unstructured":"Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain. 2012;153:1837\u201346.","journal-title":"Pain"},{"key":"4120_CR94","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S2215-0366(18)30427-9","volume":"6","author":"DC D\u2019Souza","year":"2019","unstructured":"D\u2019Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry. 2019;6:35\u201345.","journal-title":"Lancet Psychiatry"},{"key":"4120_CR95","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.biopsych.2019.07.034","volume":"87","author":"LM Mayo","year":"2020","unstructured":"Mayo LM, Asratian A, Lind\u00e9 J, Morena M, Haataja R, Hammar V, et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. Biol Psychiatry. 2020;87:538\u201347.","journal-title":"Biol Psychiatry"},{"key":"4120_CR96","unstructured":"Bhavnani, K, Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder, K Bhavnani, Editor. 2023: Jazz Pharmaceuticals."},{"key":"4120_CR97","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1021\/acsmedchemlett.5b00353","volume":"6","author":"JM Keith","year":"2015","unstructured":"Keith JM, Jones WM, Tichenor M, Liu J, Seierstad M, Palmer JA, et al. Preclinical characterization of the FAAH inhibitor JNJ-42165279. ACS Med Chem Lett. 2015;6:1204\u20138.","journal-title":"ACS Med Chem Lett"},{"key":"4120_CR98","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/cts.12548","volume":"11","author":"A Postnov","year":"2018","unstructured":"Postnov A, Schmidt ME, Pemberton DJ, de Hoon J, van Hecken A, van den Boer M, et al. Fatty acid amide hydrolase inhibition by JNJ-42165279: a multiple-ascending dose and a positron emission tomography study in healthy volunteers. Clin Transl Sci. 2018;11:397\u2013404.","journal-title":"Clin Transl Sci"},{"key":"4120_CR99","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/s41386-020-00888-1","volume":"46","author":"ME Schmidt","year":"2021","unstructured":"Schmidt ME, Liebowitz MR, Stein MB, Grunfeld J, Van Hove I, Simmons WK, et al. The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study. Neuropsychopharmacology. 2021;46:1004\u201310.","journal-title":"Neuropsychopharmacology"},{"key":"4120_CR100","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41386-020-00936-w","volume":"46","author":"MP Paulus","year":"2021","unstructured":"Paulus MP, Stein MB, Simmons AN, Risbrough VB, Halter R, Chaplan SR. The effects of FAAH inhibition on the neural basis of anxiety-related processing in healthy male subjects: a randomized clinical trial. Neuropsychopharmacology. 2021;46:1011\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"4120_CR101","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/s41386-025-02128-w","volume":"50","author":"LM Mayo","year":"2025","unstructured":"Mayo LM, Gauffin E, Petrie GN, Tansey R, Mazurka R, Haggarty CJ, et al. The efficacy of elevating anandamide via inhibition of fatty acid amide hydrolase (FAAH) combined with internet-delivered cognitive behavioral therapy in the treatment of post-traumatic stress disorder: a randomized, placebo-controlled clinical trial. Neuropsychopharmacology. 2025;50:1564\u201372.","journal-title":"Neuropsychopharmacology"},{"key":"4120_CR102","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41386-024-02001-2","volume":"50","author":"ME Klein","year":"2024","unstructured":"Klein ME, Bangerter A, Halter RJ, Cooper K, Aguilar Z, Canuso CM, et al. Efficacy and safety of JNJ-42165279, a fatty acid amide hydrolase inhibitor, in adolescents and adults with autism spectrum disorder: a randomized, phase 2, placebo-controlled study. Neuropsychopharmacology. 2024;50:480\u20137.","journal-title":"Neuropsychopharmacology"},{"key":"4120_CR103","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1002\/cmdc.201800393","volume":"13","author":"LE Kiss","year":"2018","unstructured":"Kiss LE, Beliaev A, Ferreira HS, Rosa CP, Bonifacio MJ, Loureiro AI, et al. Discovery of a potent, long-acting, and CNS-Active inhibitor (BIA 10-2474) of fatty acid amide hydrolase. ChemMedChem. 2018;13:2177\u201388.","journal-title":"ChemMedChem"},{"key":"4120_CR104","doi-asserted-by":"publisher","first-page":"104543","DOI":"10.1016\/j.yrtph.2019.104543","volume":"111","author":"SB Harris","year":"2020","unstructured":"Harris SB, Hardisty JF, Hayes AW, Weber K. Developmental and reproductive toxicity studies of BIA 10-2474. Regul Toxicol Pharmacol. 2020;111:104543.","journal-title":"Regul Toxicol Pharmacol"},{"key":"4120_CR105","doi-asserted-by":"publisher","first-page":"1066.2","DOI":"10.1096\/fasebj.31.1_supplement.1066.2","volume":"31","author":"M-J Bonifacio","year":"2017","unstructured":"Bonifacio M-J, Aires C, Loureiro AI, Moser P, Soares-da-Silva P. Pharmacological profile of BIA 10-2474, a novel FAAH inhibitor, in the rat. The FASEB Journal. 2017;31:1066.2.","journal-title":"The FASEB Journal"},{"key":"4120_CR106","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1111\/bph.14973","volume":"177","author":"MJ Bonifacio","year":"2020","unstructured":"Bonifacio MJ, Sousa F, Aires C, Loureiro AI, Fernandes-Lopes C, Pires NM, et al. Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10-2474. Br J Pharmacol. 2020;177:2123\u201342.","journal-title":"Br J Pharmacol"},{"key":"4120_CR107","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aaf7497","volume":"356","author":"ACM van Esbroeck","year":"2017","unstructured":"van Esbroeck ACM, Janssen APA, Cognetta AB 3rd, Ogasawara D, Shpak G, van der Kroeg M, et al. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science. 2017;356:1084\u20137.","journal-title":"Science"},{"key":"4120_CR108","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/10408444.2020.1867821","volume":"51","author":"AW Hayes","year":"2021","unstructured":"Hayes AW, Weber K, Moser P, Soares-da-Silva P. Non-clinical toxicology evaluation of BIA 10-2474. Crit Rev Toxicol. 2021;51:65\u201375.","journal-title":"Crit Rev Toxicol"},{"key":"4120_CR109","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1056\/NEJMoa1604221","volume":"375","author":"A Kerbrat","year":"2016","unstructured":"Kerbrat A, Ferre JC, Fillatre P, Ronziere T, Vannier S, Carsin-Nicol B, et al. Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase. N Engl J Med. 2016;375:1717\u201325.","journal-title":"N Engl J Med"},{"key":"4120_CR110","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/bcp.12920","volume":"81","author":"M Eddleston","year":"2016","unstructured":"Eddleston M, Cohen AF, Webb DJ. Implications of the BIA-102474-101 study for review of first-into-human clinical trials. Br J Clin Pharmacol. 2016;81:582\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"4120_CR111","doi-asserted-by":"publisher","first-page":"120","DOI":"10.4103\/0976-500X.189661","volume":"7","author":"R Kaur","year":"2016","unstructured":"Kaur R, Sidhu P, Singh S. What failed BIA 10-2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials. J Pharmacol Pharmacother. 2016;7:120\u20136.","journal-title":"J Pharmacol Pharmacother"},{"key":"4120_CR112","doi-asserted-by":"crossref","unstructured":"Randerson J. Fatal French clinical trial failed to check data before raising drug dose. Nature. 2016.","DOI":"10.1038\/nature.2016.21190"},{"key":"4120_CR113","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fphar.2019.00398","volume":"10","author":"K Breithaupt-Grogler","year":"2019","unstructured":"Breithaupt-Grogler K, Hardman T, de Hoon J, Donazzolo Y, Rottey S, Sourgens H, et al. The new first-in-human EMA guideline: disruptive or constructive? outcomes from the first EUFEMED discussion forum. Front Pharmacol. 2019;10:398.","journal-title":"Front Pharmacol"},{"key":"4120_CR114","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/bph.12411","volume":"171","author":"N Murataeva","year":"2014","unstructured":"Murataeva N, Straiker A, Mackie K. Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. Br J Pharmacol. 2014;171:1379\u201391.","journal-title":"Br J Pharmacol"},{"key":"4120_CR115","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/nn.2632","volume":"13","author":"JR Clapper","year":"2010","unstructured":"Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci. 2010;13:1265\u201370.","journal-title":"Nat Neurosci"},{"key":"4120_CR116","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/jphp.13166","volume":"71","author":"V Vozella","year":"2019","unstructured":"Vozella V, Ahmed F, Choobchian P, Merrill CB, Zibardi C, Tarzia G, et al. Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats. J Pharm Pharmacol. 2019;71:1762\u201373.","journal-title":"J Pharm Pharmacol"},{"key":"4120_CR117","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.phrs.2012.02.012","volume":"65","author":"O Sasso","year":"2012","unstructured":"Sasso O, Bertorelli R, Bandiera T, Scarpelli R, Colombano G, Armirotti A, et al. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Pharmacol Res. 2012;65:553\u201363.","journal-title":"Pharmacol Res"},{"key":"4120_CR118","doi-asserted-by":"publisher","first-page":"105157","DOI":"10.1016\/j.nbd.2020.105157","volume":"147","author":"R Greco","year":"2021","unstructured":"Greco R, Demartini C, Zanaboni A, Casini I, De Icco R, Reggiani A, et al. Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine. Neurobiol Dis. 2021;147:105157.","journal-title":"Neurobiol Dis"},{"key":"4120_CR119","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/bju.13223","volume":"117","author":"N Aizawa","year":"2016","unstructured":"Aizawa N, Gandaglia G, Hedlund P, Fujimura T, Fukuhara H, Montorsi F, et al. URB937, a peripherally restricted inhibitor for fatty acid amide hydrolase, reduces prostaglandin E2 -induced bladder overactivity and hyperactivity of bladder mechano-afferent nerve fibres in rats. BJU Int. 2016;117:821\u20138.","journal-title":"BJU Int"},{"key":"4120_CR120","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1007\/s10753-017-0568-7","volume":"40","author":"R Li","year":"2017","unstructured":"Li R, Chen G, Zhou L, Xu H, Tang F, Lan J, et al. The fatty acid amide hydrolase inhibitor URB937 ameliorates radiation-induced lung injury in a mouse model. Inflammation. 2017;40:1254\u201363.","journal-title":"Inflammation"},{"key":"4120_CR121","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jss.2019.01.009","volume":"239","author":"H Yin","year":"2019","unstructured":"Yin H, Li X, Xia R, Yi M, Cheng Y, Wu Y, et al. Posttreatment with the fatty acid amide hydrolase inhibitor URB937 ameliorates one-lung ventilation-induced lung injury in a rabbit model. J Surg Res. 2019;239:83\u201391.","journal-title":"J Surg Res"},{"key":"4120_CR122","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/jcbfm.2015.119","volume":"35","author":"I Boileau","year":"2015","unstructured":"Boileau I, Tyndale RF, Williams B, Mansouri E, Westwood DJ, Le Foll B, et al. The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB. J Cereb Blood Flow Metab. 2015;35:1237\u201340.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4120_CR123","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.jpsychires.2013.05.031","volume":"47","author":"JS Stevens","year":"2013","unstructured":"Stevens JS, Jovanovic T, Fani N, Ely TD, Glover EM, Bradley B, et al. Disrupted amygdala-prefrontal functional connectivity in civilian women with posttraumatic stress disorder. J Psychiatr Res. 2013;47:1469\u201378.","journal-title":"J Psychiatr Res"},{"key":"4120_CR124","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.biopsych.2025.02.894","volume":"98","author":"LD de Voogd","year":"2025","unstructured":"de Voogd LD, Hashemi MM, Zhang W, Kaldewaij R, Koch SBJ, van Ast VA, et al. Amygdala hyperactivity in posttraumatic stress disorder: disentangling predisposing from consequential factors using a prospective longitudinal design. Biol Psychiatry. 2025;98:427\u201335.","journal-title":"Biol Psychiatry"},{"key":"4120_CR125","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jaac.2018.06.017","volume":"57","author":"MK Singh","year":"2018","unstructured":"Singh MK, Leslie SM, Packer MM, Weisman EF, Gotlib IH. Limbic intrinsic connectivity in depressed and high-risk youth. J Am Acad Child Adolesc Psychiatry. 2018;57:775\u2013785.e3.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"4120_CR126","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpsychires.2023.05.010","volume":"163","author":"X Shan","year":"2023","unstructured":"Shan X, Yan H, Li H, Liu F, Xie G, Li P, et al. Abnormal causal connectivity of prefrontal-limbic circuit by structural de fi cits in drug-naive anxiety disorders. J Psychiatr Res. 2023;163:14\u201323.","journal-title":"J Psychiatr Res"},{"key":"4120_CR127","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1038\/sj.npp.1301061","volume":"31","author":"M Bortolato","year":"2006","unstructured":"Bortolato M, Campolongo P, Mangieri RA, Scattoni ML, Frau R, Trezza V, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology. 2006;31:2652\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"4120_CR128","doi-asserted-by":"publisher","first-page":"107657","DOI":"10.1016\/j.phrs.2025.107657","volume":"213","author":"MS Garcia-Gutierrez","year":"2025","unstructured":"Garcia-Gutierrez MS, Torregrosa AB, Navarrete F, Navarro D, Manzanares J. A comprehensive review of the multifaceted role of cannabinoid receptor type 2 in neurodegenerative and neuropsychiatric disorders. Pharmacol Res. 2025;213:107657.","journal-title":"Pharmacol Res"},{"key":"4120_CR129","doi-asserted-by":"publisher","first-page":"828895","DOI":"10.3389\/fpsyt.2022.828895","volume":"13","author":"H Ishiguro","year":"2022","unstructured":"Ishiguro H, Kibret BG, Horiuchi Y, Onaivi ES. Potential role of cannabinoid type 2 receptors in neuropsychiatric and neurodegenerative disorders. Front Psychiatry. 2022;13:828895.","journal-title":"Front Psychiatry"},{"key":"4120_CR130","doi-asserted-by":"publisher","first-page":"100564","DOI":"10.1016\/j.bpsgos.2025.100564","volume":"5","author":"EM Scott","year":"2025","unstructured":"Scott EM, Brown DA, Rohleder C, Shin M, Park SH, Hickie IB. A case series of young people receiving adjunctive immunotherapy for neuroimmune-mediated major mood or psychotic syndromes. Biol Psychiatry Glob Open Sci. 2025;5:100564.","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"4120_CR131","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41582-019-0174-4","volume":"15","author":"K Pape","year":"2019","unstructured":"Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry - novel perspectives on brain disorders. Nat Rev Neurol. 2019;15:317\u201328.","journal-title":"Nat Rev Neurol"},{"key":"4120_CR132","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev-clinpsy-080621-045153","volume":"19","author":"JE Bower","year":"2023","unstructured":"Bower JE, Kuhlman KR. Psychoneuroimmunology: an introduction to immune-to-brain communication and its implications for clinical psychology. Annu Rev Clin Psychol. 2023;19:331\u201359.","journal-title":"Annu Rev Clin Psychol"},{"key":"4120_CR133","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/22761","volume":"400","author":"PM Zygmunt","year":"1999","unstructured":"Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400:452\u20137.","journal-title":"Nature"},{"key":"4120_CR134","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/bph.13497","volume":"173","author":"SE O\u2019Sullivan","year":"2016","unstructured":"O\u2019Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173:1899\u2013910.","journal-title":"Br J Pharmacol"},{"key":"4120_CR135","doi-asserted-by":"publisher","first-page":"112734","DOI":"10.1016\/j.bbr.2020.112734","volume":"393","author":"A Escelsior","year":"2020","unstructured":"Escelsior A, Sterlini B, Murri MB, Serafini G, Aguglia A, da Silva BP, et al. Red-hot chili receptors: A systematic review of TRPV1 antagonism in animal models of psychiatric disorders and addiction. Behav Brain Res. 2020;393:112734.","journal-title":"Behav Brain Res"},{"key":"4120_CR136","doi-asserted-by":"publisher","first-page":"101194","DOI":"10.1016\/j.plipres.2022.101194","volume":"89","author":"ED Mock","year":"2023","unstructured":"Mock ED, Gagestein B, van der Stelt M. Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. Prog Lipid Res. 2023;89:101194.","journal-title":"Prog Lipid Res"},{"key":"4120_CR137","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.lfs.2005.05.012","volume":"77","author":"J LoVerme","year":"2005","unstructured":"LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. Life Sci. 2005;77:1685\u201398.","journal-title":"Life Sci"},{"key":"4120_CR138","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature01921","volume":"425","author":"J Fu","year":"2003","unstructured":"Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003;425:90\u20133.","journal-title":"Nature"},{"key":"4120_CR139","doi-asserted-by":"crossref","unstructured":"Kumar, BR, Merck\u2013Schering-Plough Corp Merger, in Wealth Creation in the World\u2019s Largest Mergers and Acquisitions: Integrated Case Studies, BR Kumar, Editor. 2019, Cham: Springer International Publishing. p.301-7.","DOI":"10.1007\/978-3-030-02363-8_36"},{"key":"4120_CR140","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1124\/pr.113.007450","volume":"65","author":"J Uetrecht","year":"2013","unstructured":"Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev. 2013;65:779\u2013808.","journal-title":"Pharmacol Rev"},{"key":"4120_CR141","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/cpt.2290","volume":"111","author":"JF Rocha","year":"2022","unstructured":"Rocha JF, Santos A, Gama H, Moser P, Falcao A, Pressman P, et al. Safety, tolerability, and pharmacokinetics of FAAH Inhibitor BIA 10-2474: a double-blind, randomized, placebo-controlled study in healthy volunteers. Clin Pharmacol Ther. 2022;111:391\u2013403.","journal-title":"Clin Pharmacol Ther"},{"key":"4120_CR142","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/cmdc.201500469","volume":"11","author":"C Gonzalez-Bello","year":"2016","unstructured":"Gonzalez-Bello C. Designing irreversible inhibitors\u2013worth the effort?. ChemMedChem. 2016;11:22\u201330.","journal-title":"ChemMedChem"},{"key":"4120_CR143","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-4020-8831-5_4","volume":"49","author":"F Fezza","year":"2008","unstructured":"Fezza F, De Simone C, Amadio D, Maccarrone M. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell Biochem. 2008;49:101\u201332.","journal-title":"Subcell Biochem"},{"key":"4120_CR144","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/092986607780090829","volume":"14","author":"BS Basavarajappa","year":"2007","unstructured":"Basavarajappa BS. Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett. 2007;14:237\u201346.","journal-title":"Protein Pept Lett"},{"key":"4120_CR145","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-3-319-20825-1_2","volume":"231","author":"MG Cascio","year":"2015","unstructured":"Cascio MG, Marini P. Biosynthesis and Fate of Endocannabinoids. Handb Exp Pharmacol. 2015;231:39\u201358.","journal-title":"Handb Exp Pharmacol"},{"key":"4120_CR146","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lfs.2018.04.054","volume":"204","author":"M Toczek","year":"2018","unstructured":"Toczek M, Malinowska B. Enhanced endocannabinoid tone as a potential target of pharmacotherapy. Life Sci. 2018;204:20\u201345.","journal-title":"Life Sci"},{"key":"4120_CR147","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/joim.13229","volume":"290","author":"CJ Fowler","year":"2021","unstructured":"Fowler CJ. The endocannabinoid system - current implications for drug development. J Intern Med. 2021;290:2\u201326.","journal-title":"J Intern Med"},{"key":"4120_CR148","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1124\/jpet.112.201426","volume":"345","author":"SG Kinsey","year":"2013","unstructured":"Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF, et al. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther. 2013;345:492\u2013501.","journal-title":"J Pharmacol Exp Ther"},{"key":"4120_CR149","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.phrs.2011.04.010","volume":"64","author":"NR Sciolino","year":"2011","unstructured":"Sciolino NR, Zhou W, Hohmann AG. Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res. 2011;64:226\u201334.","journal-title":"Pharmacol Res"},{"key":"4120_CR150","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/npp.2014.24","volume":"39","author":"P Zhong","year":"2014","unstructured":"Zhong P, Wang W, Pan B, Liu X, Zhang Z, Long JZ, et al. Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology. 2014;39:1763\u201376.","journal-title":"Neuropsychopharmacology"},{"key":"4120_CR151","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/mds.28681","volume":"36","author":"KR Muller-Vahl","year":"2021","unstructured":"Muller-Vahl KR, Fremer C, Beals C, Ivkovic J, Loft H, Schindler C. Monoacylglycerol lipase inhibition in tourette syndrome: a 12-week, randomized, controlled study. Mov Disord. 2021;36:2413\u20138.","journal-title":"Mov Disord"},{"key":"4120_CR152","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/nn.2616","volume":"13","author":"JE Schlosburg","year":"2010","unstructured":"Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci. 2010;13:1113\u20139.","journal-title":"Nat Neurosci"},{"key":"4120_CR153","doi-asserted-by":"publisher","first-page":"20270","DOI":"10.1073\/pnas.0909411106","volume":"106","author":"JZ Long","year":"2009","unstructured":"Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA. 2009;106:20270\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4120_CR154","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1021\/acschemneuro.1c00699","volume":"13","author":"S Bajaj","year":"2022","unstructured":"Bajaj S, Zameer S, Jain S, Yadav V, Vohora D. Effect of the MAGL\/FAAH dual inhibitor JZL-195 on streptozotocin-induced alzheimer\u2019s disease-like sporadic dementia in mice with an emphasis on abeta, HSP-70, neuroinflammation, and oxidative stress. ACS Chem Neurosci. 2022;13:920\u201332.","journal-title":"ACS Chem Neurosci"},{"key":"4120_CR155","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.3390\/cells10102543","volume":"10","author":"R Greco","year":"2021","unstructured":"Greco R, Demartini C, Francavilla M, Zanaboni AM, Tassorelli C. Dual inhibition of FAAH and MAGL counteracts migraine-like pain and behavior in an animal model of migraine. Cells. 2021;10:2543.","journal-title":"Cells"},{"key":"4120_CR156","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1152\/jn.00570.2019","volume":"123","author":"EA Fucich","year":"2020","unstructured":"Fucich EA, Stielper ZF, Cancienne HL, Edwards S, Gilpin NW, Molina PE, et al. Endocannabinoid degradation inhibitors ameliorate neuronal and synaptic alterations following traumatic brain injury. J Neurophysiol. 2020;123:707\u201317.","journal-title":"J Neurophysiol"},{"key":"4120_CR157","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/FBP.0000000000000603","volume":"33","author":"LP Iglesias","year":"2022","unstructured":"Iglesias LP, Aguiar DC, Moreira FA. TRPV1 blockers as potential new treatments for psychiatric disorders. Behav Pharmacol. 2022;33:2\u201314.","journal-title":"Behav Pharmacol"},{"key":"4120_CR158","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1017\/neu.2016.68","volume":"29","author":"C Kirkedal","year":"2017","unstructured":"Kirkedal C, Wegener G, Moreira F, Joca SRL, Liebenberg N. A dual inhibitor of FAAH and TRPV1 channels shows dose-dependent effect on depression-like behaviour in rats. Acta Neuropsychiatr. 2017;29:324\u20139.","journal-title":"Acta Neuropsychiatr"},{"key":"4120_CR159","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phrs.2014.04.014","volume":"87","author":"A Navarria","year":"2014","unstructured":"Navarria A, Tamburella A, Iannotti FA, Micale V, Camillieri G, Gozzo L, et al. The dual blocker of FAAH\/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. Pharmacol Res. 2014;87:151\u20139.","journal-title":"Pharmacol Res"},{"key":"4120_CR160","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.neuroscience.2016.10.031","volume":"340","author":"AG Sartim","year":"2017","unstructured":"Sartim AG, Moreira FA, Joca SRL. Involvement of CB(1) and TRPV1 receptors located in the ventral medial prefrontal cortex in the modulation of stress coping behavior. Neuroscience. 2017;340:126\u201334.","journal-title":"Neuroscience"},{"key":"4120_CR161","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/npp.2008.98","volume":"34","author":"V Micale","year":"2009","unstructured":"Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F, et al. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology. 2009;34:593\u2013606.","journal-title":"Neuropsychopharmacology"},{"key":"4120_CR162","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1177\/0269881117691567","volume":"31","author":"PH Gobira","year":"2017","unstructured":"Gobira PH, Lima IV, Batista LA, de Oliveira AC, Resstel LB, Wotjak CT, et al. N-arachidonoyl-serotonin, a dual FAAH and TRPV1 blocker, inhibits the retrieval of contextual fear memory: Role of the cannabinoid CB1 receptor in the dorsal hippocampus. J Psychopharmacol. 2017;31:750\u20136.","journal-title":"J Psychopharmacol"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04120-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04120-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04120-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T17:03:56Z","timestamp":1779987836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04120-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":162,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4120"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04120-4","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships: FML is a shareholder of curantis UG (Ltd.). CR is a shareholder of lero bioscience UG (Ltd.). CR, FRG, AEH, and FML report financial support as full- or part-time employees of Endosane\u00ae Pharmaceuticals GmbH. FML received an Investigator Initiated Trial Grant from Endosane\u00ae Pharmaceuticals GmbH. The remaining authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethic Statement is not applicable to this manuscript as no new human data were created or analysed in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"288"}}